FBT

First Trust NYSE Arca Biotechnology Index Fund

Up$131.82
+$0.98
(+0.75%)
As of 1:00:49 PM EDT | 9/19/19  |  Market Open

FBT Trading Data

Open

$130.78

Low Price

$130.78

High Price

$131.84

Previous Last Price

$130.84

Bid Size

$131.74 X 1300

Ask Size

$131.82 X 100

FBT Portfolio Data

AUM

$1,910,810,000

Shares

14,500

PE Ratio

19.68

Price / Book Ratio

4.78

Expense Ratio

0.57

Net Asset Value

$131.78

Volume

Volume

186,692

Avg. Volume (YDT)

179,135

Dollar Volume

$11,048,665

Weekly Avg. Volume

1,352,859

Monthly Avg. Volume

568,125

Quarterly Avg. Volume

232,491

FBT Fund Description

The First Trust NYSE Arca Biotechnology Index Fund is and exchange-traded index fund. The investment objective of the fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. The NYSE Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics. The index is rebalanced quarterly based on closing prices on the third Friday in January, April, July and October to ensure that each component stock continues to represent approximately equal weight in the index.

FBT Chart

FBT Summary

Fund Family

First Trust Portfolios

Tracks This Index

First Trust NYSE Arca Biotechnology Index Fund

Inception Date

2006-06-19

Asset Class

Equity

Asset Class Size

Biotech

FBT Classification

Region (General)

Global

Region (Specific)

Sector

Health Care

Equity Index

Leveraged Family

FBT Holdings

Top 10 Holdings

ACADIA Pharmaceuticals Inc. (ACAD)
5.68%
Alnylam Pharmaceuticals Inc. (ALNY)
3.96%
Neurocrine Biosciences Inc. (NBIX)
3.93%
Amgen Inc. (AMGN)
3.91%
United Therapeutics Corporation (UTHR)
3.85%
Gilead Sciences Inc. (GILD)
3.65%
Biogen Inc. (BIIB)
3.56%
Intercept Pharmaceuticals Inc. (ICPT)
3.49%
Vertex Pharmaceuticals Incorporated (VRTX)
3.48%
Incyte Corporation (INCY)
3.42%

Total FBT Holdings

Total Holdings: 31

ACADIA Pharmaceuticals Inc. (ACAD)
5.68%
Alnylam Pharmaceuticals Inc. (ALNY)
3.96%
Neurocrine Biosciences Inc. (NBIX)
3.93%
Amgen Inc. (AMGN)
3.91%
United Therapeutics Corporation (UTHR)
3.85%
Gilead Sciences Inc. (GILD)
3.65%
Biogen Inc. (BIIB)
3.56%
Intercept Pharmaceuticals Inc. (ICPT)
3.49%
Vertex Pharmaceuticals Incorporated (VRTX)
3.48%
Incyte Corporation (INCY)
3.42%
IQVIA Holdings Inc. (IQV)
3.42%
Charles River Laboratories International Inc. (CRL)
3.39%
Regeneron Pharmaceuticals Inc. (REGN)
3.37%
Alkermes Plc (ALKS)
3.36%
Exact Sciences Corporation (EXAS)
3.36%
Illumina Inc. (ILMN)
3.34%
Grifols S.A. (ADR) (GRFS)
3.3%
Seattle Genetics Inc. (SGEN)
3.24%
Ionis Pharmaceuticals Inc. (IONS)
3.23%
Alexion Pharmaceuticals Inc. (ALXN)
3.21%
Exelixis Inc. (EXEL)
3.21%
BioMarin Pharmaceutical Inc. (BMRN)
3.2%
Bio-Techne Corporation (TECH)
3.18%
FibroGen Inc. (FGEN)
3.16%
QIAGEN N.V. (QGEN)
3%
Agios Pharmaceuticals Inc. (AGIO)
2.69%
bluebird bio Inc. (BLUE)
2.61%
Ultragenyx Pharmaceutical Inc. (RARE)
2.46%
Nektar Therapeutics (NKTR)
2.21%
Sarepta Therapeutics Inc. (SRPT)
2.16%
First Trust NYSE Arca Biotechnology Index Fund (FBT)
0%

FBT Technicals

Alpha

-2.16

Beta

1.49

Leverage

Long

Standard Deviation

8.39

FBT Dividends

Dividend Date

2015-09-23

Latest Dividend

0.02

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

FBT Performance

YTD Return

6.09%

1 Year Return

-12.79%

3 Year Return

28.43%

5 Year Return

41.1%

10 Year Return

367.29%

FBT Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.